Search the Newsreel

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Matthew GlineInvestor Relations - Stephanie Lee Griffin TAKEAWAYS Cash and Cash Equivalents -- $797.8 million as of June 30, 2026, which management stated provides …

Immunovant stock hits 52-week high at 41.37 USD

Immunovant Inc.'s stock reached a 52-week high of $41.37, reflecting a 169% total return over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. Separately, Roivant Sciences, a related entity, reported …

The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT

The Manufacturers Life Insurance Company reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 47.1% in the first quarter, selling over 45,000 shares but retaining 51,421 shares valued at $1.28 million. Despite this, other institutional investors have increased their positions. Immunovant reported a wider-than-expected quarterly …

Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts

Immunovant, Inc. (NASDAQ:IMVT) has received an average recommendation of "Moderate Buy" from ten analysts, with an average twelve-month price target of $44.00. Recent analyst reports show several price target increases and "buy" ratings. Insider transactions indicate recent sales by the COO and CTO, while …

Liquidity Mapping Around (IMVT) Price Events

This article provides a liquidity mapping analysis for Immunovant Inc. (NASDAQ: IMVT), highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The …

Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT

Hennion & Walsh Asset Management Inc. significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 32.6% in the second quarter, now holding 120,686 shares valued at $4.65 million. Despite this institutional confidence and a "Moderate Buy" consensus rating from analysts, Immunovant reported a wider-than-expected …

Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT

Renaissance Technologies LLC has acquired a new stake of $4.78 million in Immunovant, Inc. (NASDAQ:IMVT), while institutional investors collectively own 47.08% of the company's stock. Despite analysts maintaining a "Moderate Buy" rating with an average target price of $44, Immunovant insiders have sold approximately …

Immunovant, Inc. Q1 2027 Earnings Call Summary

Immunovant, Inc. Q1 2027 Earnings Call Summary - Moby Strategic Execution and Pipeline Acceleration Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Immunovant Q1 Earnings Call Highlights

Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary

Immunovant, Inc. reported a net loss of $153.2 million for Q1 2027, an increase from $120.6 million in the prior year, with diluted loss per share at $(0.75). The company generated no revenues for the quarter and is focusing on the development of IMVT-1402 …

Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside

Immunovant, Inc.'s stock price target has been increased to $47.56 from $47.06 by 16 analysts, implying a 21% potential upside based on its Aug. 5 closing price. The consensus rating remains "Buy," with 12 analysts recommending Buy and 4 recommending Hold.

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials …

Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026

Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with …

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant (Nasdaq: IMVT) announced its corporate updates and financial results for the first fiscal quarter ended June 30, 2026. The company's IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected for various trials between calendar years 2026 and 2028. …

Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch

Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient …

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant …

IMVT Maintained by JP Morgan -- Price Target Raised to $50.00

JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The …

Immunovant (IMVT) Stock Forum and Discussion

This page provides a stock forum and discussion platform for Immunovant (IMVT). It allows investors and interested parties to share insights, opinions, and analysis related to the company's stock performance and future prospects. The forum serves as a community hub for active engagement on …

Immunovant (IMVT.US) will release its earnings report before the market opens on August 6.

Immunovant (IMVT.US) is scheduled to release its earnings report before the market opens on August 6. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.

Immunovant (Nasdaq:IMVT) - Stock Analysis

This Simply Wall St analysis of Immunovant (IMVT) provides an overview of the company's financial health, future growth prospects, past performance, and insider transactions. It highlights the company's focus on developing targeted therapies for autoimmune diseases, particularly IMVT-1402, and discusses recent news, analyst ratings, …

Why (IMVT) Price Action Is Critical for Tactical Trading

This article provides a critical analysis of Immunovant Inc. (IMVT) stock's price action for tactical trading, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …

Immunovant (IMVT) Projected to Announce Earnings on Thursday

Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT

This page provides financial overview for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the market is closed with no trades. The article is primarily a navigation and information hub for financial data on Immunovant, Inc., mentioning sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," …

Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immunovant Inc (IMVT)'s dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents other financial data …

Immunovant Inc (IMVT) Cash Flow

This article provides a detailed cash flow statement for Immunovant Inc (IMVT), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also …

Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immunovant Inc (IMVT), listing major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters and an overview of related ETF holdings. Key holders include Roivant …

Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immunovant Inc (IMVT), covering key indicators like MACD, RSI, and Moving Averages. It summarizes the current signals for IMVT, indicating an overall neutral signal based on today's moving averages and other technical indicators. The analysis notes 5 …

Form 4 Immunovant Inc For: 24 July By Investing.com

This article reports on the filing of Form 4 for Immunovant Inc. on July 24, as published by Investing.com. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in beneficial …

Immunovant (IMVT) CTO sells 2,857 shares in mandated tax sell-to-cover

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,857 shares of common stock on July 23, 2026, at a weighted average price of $38.69 per share. This transaction was a mandated "sell-to-cover" to fulfill tax withholding obligations tied to the vesting of 6,250 restricted …

Immunovant CTO Jay Stout sells $110,537 in shares

Immunovant CTO Jay S. Stout sold 2,857 shares of the company's common stock for $110,537 to cover tax withholding obligations related to restricted stock units. This "sell to cover" transaction was a mandatory act as per company policy, not a discretionary sale. Immunovant shares …